NCT03152084

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function

Conditions

• Diabetes Mellitus, Type 2
• Kidney Function Tests

Interventions

Type	Name	Description
DRUG	Dapagliflozin	The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.

Timeline

• Start date: 2017-07-12
• Primary completion: 2020-03-20
• Completion: 2020-03-20
• First posted: 2017-05-12
• Last updated: 2021-05-28
• Results posted: 2021-05-28

Locations

4 sites across 2 countries: Netherlands, Sweden